• 제목/요약/키워드: Hematologic neoplasms

검색결과 29건 처리시간 0.024초

A retrospective study of 16 cats with intermediate- to high-grade alimentary lymphoma

  • Kwak, Dong-Hyuk;Cho, Mun-Ju;Park, Hyung-Jin;Song, Kun-Ho;Seo, Kyoung Won
    • 대한수의학회지
    • /
    • 제61권1호
    • /
    • pp.8.1-8.10
    • /
    • 2021
  • The purpose of this retrospective study was to describe cases of feline intermediateto high-grade alimentary lymphoma regarding signalment, clinical presentation, laboratory findings, response to therapy (modified 25-week University of Wisconsin-Madison [UW-25] vs. COP [cyclophosphamide, vincristine, prednisone]), toxicosis, and outcomes and to identify prognostic factors. Sixteen cats were treated with chemotherapy protocols. Response rates and survival did not differ statistically between the two protocols. The progression-free interval (PFI) and median survival time (MST) in cats achieving a response to therapy were longer than in those with no response [NR] (complete remission [CR] vs. partial remission [PR] vs. NR; PFI, 124 vs. 49 vs. 12 days, p < 0.001; MST, 361 vs. 118 vs. 16 days, p < 0.001). Clinical stage was another prognostic factor for PFI and MST. The PFI and MST in cats in stage I were longer than in those in other stages (PFI, 107 days vs. 30 days; MST, 193 days vs. 54 days). Hematologic and gastrointestinal toxicosis was mostly low grade. In comparing the modified UW-25 protocol with the COP protocol, there was not much difference in the number of neutropenic episodes and grade levels.

Surgery for Pulmonary Fungal Infections Complicating Hematological Malignancies

  • Yamamichi, Takashi;Horio, Hirotoshi;Asakawa, Ayaka;Okui, Masayuki;Harada, Masahiko
    • Journal of Chest Surgery
    • /
    • 제51권5호
    • /
    • pp.350-355
    • /
    • 2018
  • Background: The complication rate of fungal disease is higher among patients with hematological malignancies. We investigated the clinicobacteriological outcomes of resected pulmonary fungal infections complicating hematological malignancies. Methods: Between 2001 and 2017, 21 patients with pulmonary fungal infections complicating hematological malignancies underwent resection, and their clinical records and survival were retrospectively reviewed. Results: The median age of the patients was 47 years, and 13 were male. The histological diagnoses were pulmonary aspergillosis (19 cases), mucormycosis (1 case), and cryptococcosis (1 case). The indications for surgery were resistance to antifungal therapy and the necessity of surgery before hematopoietic stem cell transplantation in 13 and 8 cases, respectively. The diagnoses of the hematological malignancies were acute myelogenous leukemia (10 cases), acute lymphocytic leukemia (5 cases), myelodysplastic syndrome (3 cases), and chronic myelogenous leukemia, malignant lymphoma, and extramedullary plasmacytoma (1 case each). The surgical procedures were partial resection (11 cases), segmentectomy (5 cases), lobectomy (4 cases), and cavernostomy (1 case). The size of the lesions was 0.9-8.5 cm. Fourteen cases had cavitation. There were no surgical-related deaths or fungal progression. Conclusion: Pulmonary fungal infections are resistant to treatments for hematological malignancies. Since the treatment of the underlying disease is extended and these infections often recur and are exacerbated, surgery should be considered when possible.

경화 양상으로 나타난 폐의 Mucormycosis (Pulmonary Mucormycosis with an Appearance of Consolidation)

  • 김신재;이홍범;이용철;이양근
    • Tuberculosis and Respiratory Diseases
    • /
    • 제49권1호
    • /
    • pp.117-121
    • /
    • 2000
  • 폐모균증은 치명적인 결과를 초래하는 기회감염으로 조기진단 및 치료가 요망된다. 하지만 본 증례와 같이 폐모균증의 방사선학적 소견은 비특이적이므로 조기 진단이 용이하지 않다. 이에 저자들은 폐모균종의 발생 위험인자를 내포한 환자가 항생제에 반응을 보이지 않으면서 방사선 소견상 폐의 경화, 종괴, 결절, 공동 등의 소견을 보이는 경우 폐모균증올 고려함이 필요하다고 생각되어 문헌고찰과 함께 본 증례를 보고하는 바이다.

  • PDF

Pericardial Window Operation in Oncology Patients: Analysis of Long-Term Survival and Prognostic Factors

  • Sung Min Kim;Jun Ho Lee;Su Ryeun Chung;Kiick Sung;Wook Sung Kim;Yang Hyun Cho
    • Journal of Chest Surgery
    • /
    • 제57권2호
    • /
    • pp.169-177
    • /
    • 2024
  • Background: Pericardial effusion (PE) is a serious condition in cancer patients, primarily arising from malignant dissemination. Pericardial window formation is a surgical intervention for refractory PE. However, the long-term outcomes and factors associated with postoperative survival remain unclear. Methods: We retrospectively analyzed data from 166 oncology patients who underwent pericardial window formation at Samsung Medical Center between 2011 and 2023. We analyzed survival and PE recurrence regarding surgical approach, cancer type, and cytopathological findings. To identify factors associated with survival, we utilized Cox proportional-hazards regression. Results: All patients had tumors documented in accordance with the American Joint Committee on Cancer staging manual, including lung (61.4%), breast (9.6%), gastrointestinal (9.0%), hematologic (3.6%), and other cancers (16.4%). Surgical approaches included mini-thoracotomy (67.5%) and thoracoscopy (32.5%). Postsurgical cytopathology confirmed malignancy in 94 cases (56.6%). Over a median follow-up duration of 50.0 months, 142 deaths and 16 PE recurrences occurred. The 1-year overall and PE recurrence-free survival rates were 31.4% and 28.6%, respectively. One-year survival rates were significantly higher for thoracoscopy recipients (43.7% vs. 25.6%, p=0.031) and patients with negative cytopathology results (45.1% vs. 20.6%, p<0.001). No significant survival difference was observed between lung cancer and other types (p=0.129). Multivariate analysis identified New York Heart Association class, cancer stage, and cytopathology as independent prognostic factors. Conclusion: This series is the largest to date concerning window formation among cancer patients with PE. Patients' long-term survival after surgery was generally unfavorable. However, cases with negative cytopathology or earlier tumor stage demonstrated comparatively high survival rates.

Serological response 5 months after the BNT162b2 COVID-19 vaccination in patients with various hematological disorders in Japan

  • Yoshiaki Marumo;Takashi Yoshida;Yuki Furukawa;Kenji Ina;Ayumi Kamiya;Takae Kataoka;Satoshi Kayukawa
    • Clinical and Experimental Vaccine Research
    • /
    • 제12권4호
    • /
    • pp.319-327
    • /
    • 2023
  • Purpose: Patients with hematological malignancies are at an increased risk of severe infection with coronavirus disease 2019 (COVID-19). However, developing an adequate immune response after vaccination is difficult, especially in patients with lymphoid neoplasms. Since the long-term effects of the BNT162b2 vaccine are unclear, the humoral immune response 5 months after the two vaccinations in patients with hematological disorders was analyzed. Materials and Methods: Samples were collected from 96 patients vaccinated twice with BNT162b2 and treated with at least one line of an antitumor or immunosuppressive drug in our hospital from November 2021 to February 2022. Serum anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) spike (S) antibody titers were analyzed. Patients were age- and sex-matched using propensity matching and compared with a healthy control group. Patients with serum anti-SARS-CoV-2 S antibodies were defined as 'responder' if >50 U/mL. The patients had B-cell non-Hodgkin lymphoma (B-NHL), multiple myeloma, chronic myeloid leukemia, etc. Results: Patients had significantly low antibody levels (median, 55.3 U/mL vs. 809.8 U/mL; p<0.001) and a significantly low response rate (p<0.001). Multivariate analysis showed that patients with B-NHL, aged >72 years, were associated with a low response to vaccination. There were no significant differences between patients with chronic myeloid leukemia and healthy controls. Conclusion: Our study shows that patients with hematological disorders are at risk of developing severe COVID-19 infections because of low responsiveness to vaccination. Moreover, the rate of antibody positivity differed between the disease groups. Further studies are warranted to determine an appropriate preventive method for these patients, especially those with B-NHL.

우리나라 일개 병원 암 환자에서 중심정맥관 합병증에 관한 후향적 조사 (Retrospective Analysis for Complications of the Central Venous Catheter in Patients with Cancer at a Single Center in Korea)

  • 김은정;김현정;김한조;김경하;김세형;이상철;배상병;김찬규;이남수;이규택;박성규;원종호;박희숙;홍대식
    • Journal of Hospice and Palliative Care
    • /
    • 제13권1호
    • /
    • pp.24-31
    • /
    • 2010
  • 목적: 암환자에게 있어 중심 정맥관 삽입은 항암치료나 수혈, 비경구 영양공급 목적으로 흔히 시행된다. 중심정맥관 삽입으로 인해 발생하는 합병증으로는 감염, 혈전, 물리적 합병증이 있는데, 이 연구는 합병증의 빈도와 관련 인자들을 규명하기 위해 계획되었다. 방법: 2001년 3월부터 2006년 8월까지 중심 정맥관을 삽입한 고형암과 혈액암 환자를 대상으로 경과기록 분석을 통한 후향적 연구를 시행하였다. 감염, 혈전, 물리적 합병증 각각의 빈도를 조사하였고, 감염과 혈전의 발생에 영향을 미치는 여러 인자들과 그 연관성을 분석하기 위해 교차 분석을 사용하였다. 또한, 삽입관 수명에 영향을 미치는 인자들을 알기 위해 단변량 분석에는 log-rank test를 이용한 Kaplan-Meier 방법과 다변량 분석에는 Cox regression analysis 를 사용하였다. 결과: 310명의 암환자들에게 310개의 중심 정맥관 삽입이 시술되었고, 남자 157명, 여자 153명이었고, 혈액암 환자가 132명, 고형암 환자 178명이었으며, 평균 연령은 52세였다(range: 15~82). 60예(19%)의 환자에서 합병증이 나타났으며, 혈전을 가진 환자에서 감염이 더 빈번하게 일어났고(P=0.003), 암이나 삽입관의 종류, 수혈 및 비경구 영양 시행 여부와 합병증 발생과는 큰 연관성이 없었다. 삽입관의 평균수명은 99일(range: 2~1,330)이었는데 삽입관의 수명은 터널식 삽입관(P=0.000)을 가진 경우에, 그리고 중심정맥관을 통해 수혈을 하지 않은 경우(P=0.030) 더 연장되었다. 결론: 중심 정맥관 삽입의 주요 합병증은 혈전과 감염이었다. 터널식 정맥관은 장기적인 사용에 효과적인 방법이며, 특히 중심정맥관을 통해 수혈을 받지 않는 경우에 그러하다. 중심 정맥관 장기 사용을 위해 혈전과 감염의 예방 및 치료에 대한 연구가 더욱 이루어져야할 것으로 여겨진다.

Simultaneous integrated boost intensity-modulated radiotherapy versus 3-dimensional conformal radiotherapy in preoperative concurrent chemoradiotherapy for locally advanced rectal cancer

  • Bae, Bong Kyung;Kang, Min Kyu;Kim, Jae-Chul;Kim, Mi Young;Choi, Gyu-Seog;Kim, Jong Gwang;Kang, Byung Woog;Kim, Hye Jin;Park, Soo Yeun
    • Radiation Oncology Journal
    • /
    • 제35권3호
    • /
    • pp.208-216
    • /
    • 2017
  • Purpose: To evaluate the feasibility of simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) for preoperative concurrent chemoradiotherapy (PCRT) in locally advanced rectal cancer (LARC), by comparing with 3-dimensional conformal radiotherapy (3D-CRT). Materials and Methods: Patients who were treated with PCRT for LARC from 2015 January to 2016 December were retrospectively enrolled. Total doses of 45 Gy to 50.4 Gy with 3D-CRT or SIB-IMRT were administered concomitantly with 5-fluorouracil plus leucovorin or capecitabine. Surgery was performed 8 weeks after PCRT. Between PCRT and surgery, one cycle of additional chemotherapy was administered. Pathologic tumor responses were compared between SIB-IMRT and 3D-CRT groups. Acute gastrointestinal, genitourinary, hematologic, and skin toxicities were compared between the two groups based on the RTOG toxicity criteria. Results: SIB-IMRT was used in 53 patients, and 3D-CRT in 41 patients. After PCRT, no significant differences were noted in tumor responses, pathologic complete response (9% vs. 7%; p = 1.000), pathologic tumor regression Grade 3 or higher (85% vs. 71%; p = 0.096), and R0 resection (87% vs. 85%; p = 0.843). Grade 2 genitourinary toxicities were significantly lesser in the SIB-IMRT group (8% vs. 24%; p = 0.023), but gastrointestinal toxicities were not different across the two groups. Conclusion: SIB-IMRT showed lower GU toxicity and similar tumor responses when compared with 3D-CRT in PCRT for LARC.

Effect of leukocyte alteration on treatment outcomes following preoperative chemoradiotherapy in patients with rectal cancer

  • Kim, Tae Gyu;Park, Won;Choi, Doo Ho;Park, Hee Chul;Kim, Seok-Hyung;Cho, Yong Beom;Yun, Seong Hyen;Kim, Hee Cheol;Lee, Woo Yong;Lee, Jeeyun;Park, Joon Oh;Park, Young Suk
    • Radiation Oncology Journal
    • /
    • 제35권3호
    • /
    • pp.217-226
    • /
    • 2017
  • Purpose: Hematotoxicity following anti-cancer treatment is known to be related to treatment efficacy in several malignancies. The purpose of this study was to examine the hematologic parameters related to the tumor response and survival in patients treated with curative surgery following preoperative chemoradiotherapy (CRT) for rectal cancer. Materials and Methods: Four hundred eighteen patients with rectal cancer who underwent preoperative CRT and curative surgery were analyzed, retrospectively. The main clinical factors and blood cell counts before and after CRT were investigated with respect to their relationships with tumor downstaging and patient survival. Results: The post-CRT leukocyte count was significantly different between the tumor downstaging group and the non-downstaging group (median, 4740/uL vs. 5130/uL; p = 0.013). Multivariate analysis showed that histological grade, circumferential extent, and post-CRT leukocyte count were related to tumor downstaging. In addition, histological grade, post-CRT leukocyte count, and tumor downstaging were related to disease-free survival. The 5-year disease-free survival and overall survival in patients with post-CRT leukocyte count ${\leq}3730/uL$, which is the cut-off value derived from the receiver operation characteristic (ROC) curve analysis, were significantly higher than those with higher counts (88.0% vs. 71.6%, p = 0.001; 94.4% vs. 84.1%, p = 0.024). Conclusion: Post-CRT leukocyte count of ${\leq}3730/uL$ could be regarded as a good prognostic factor for tumor response and survival in rectal cancer patients treated with preoperative CRT.

Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: preliminary results of a randomized controlled trial

  • Aghili, Mahdi;Khalili, Nastaran;Khalili, Neda;Babaei, Mohammad;Farhan, Farshid;Haddad, Peiman;Salarvand, Samaneh;Keshvari, Amir;Fazeli, Mohammad Sadegh;Mohammadi, Negin;Ghalehtaki, Reza
    • Radiation Oncology Journal
    • /
    • 제38권2호
    • /
    • pp.119-128
    • /
    • 2020
  • Purpose: Colorectal cancer is becoming an increasing concern in the middle-aged population of Iran. This study aimed to compare the preliminary results of short-course and long-course neoadjuvant chemoradiotherapy treatment for rectal cancer patients. Materials and Methods: In this clinical trial we recruited patients with rectal adenocarcinoma located from 5 cm to 15 cm above the anal verge. Patients in group I (short-course) received three-dimensional conformational radiotherapy with a dose of 25 Gy/5 fractions in 1 week plus concurrent XELOX regimen (capecitabine 625 mg/㎡ from day 1-5 twice daily and oxaliplatin 50 mg/㎡ on day 1 once daily). Patients in group II (long-course) received a total dose of 50-50.4 Gy/25-28 fractions for 5 to 5.5 weeks plus capecitabine 825 mg/㎡ twice daily. Both groups underwent consolidation chemotherapy followed by delayed surgery at least 8 weeks after radiotherapy completion. The pathological response was assessed with tumor regression grade. Results: In this preliminary report on complications and pathological response, 66 patients were randomized into two study groups. Mean duration of radiotherapy in the group II (long-course) was 5 ± 1 days (range, 5 to 8 days) and 38 ± 6 days (range, 30 to 58 days). The median follow-up was 18 months. Pathological complete response was achieved in 32.3% and 23.1% of patients in the shortcourse and long-course groups, respectively (p = 0.558). Overall, acute grade 3 or higher treatment-related toxicities occurred in 24.2% and 22.2% of patients in group I and II, respectively (p = 0.551). No acute grade 4 or 5 adverse events were observed in either group except one grade 4 hematologic toxicity that was seen in group II. Within one month of surgery, no significant difference was seen regarding grade ≥3 postoperative complications (p = 0.333). Conclusion: For patients with rectal cancer located at least 5 cm above the anal verge, short-course radiotherapy with concurrent and consolidation chemotherapy and delayed surgery is not different in terms of acute toxicity, postoperative morbidity, complete resection, and pathological response compared to long-course chemoradiotherapy.